

Figure 1A: Migration of Human aortic endothelial cells in response to IGD tripeptide, capped IGD tripeptide. A dose dependent effect was observed with the optimal concentration being 100 μM for the uncapped peptide. However, with the capped peptide better migration compared to the uncapped peptide was observed at a 10–fold lower concentration. The respective scramble peptides showed fewer number of cells migrating (data not shown)

Figure 1B: Migration of human aortic smooth muscle cells in response to the tripeptide





Figure 1C: This figure shows the migration of endothelial cells in a modified Boyden chamber assay in response to various treatments. Both IGD and GGIGDGG cause increased migratory response compared to either the negative control or the corresponding scramble peptides.



Figure 2

Proliferation of Human aortic endothelial cells in response to treatment with IGD tripeptide, the capped IGD tripeptide, and capped and uncapped scramble tripeptide, at two different concentrations. It can be seen that with the capped tripeptide the proliferative response was nearly twice as that of the uncapped tripeptide. In either case the scramble peptides showed a significantly lower response than the active peptides



Figure 3A: Quail CAM assay showing increase in blood vessels in response to the peptide and the capped peptide compared to the respective scramble peptides. Data presented here is as a percent change over negative control, the negative being set at 100%. It can be seen that the capped peptide was better that the uncapped peptide at equivalent concentrations.

Quail CAM Assay with Peptides



Figure 3B: Angiogenic response of the capped IGD-motif in the quail CAM assay. The vessel density in 7 days old quail embryos treated with the capped IGD motif (GGIGDGG) resulted in increased vessel density compared to either the carrier alone (povidone) or the scramble peptide (GGDIGGG) treatment.



Figure 4: UV-VIS spectra comparison of cerivastatin released from EVA film and pure cerivastatin in deionized water



Figure 5: Cerivastatin release profile from EVA film wrapped on a stent

Figure 6: Release of cerivastatin from liquid vitamin E carrier